tRNA-Splicing Ligase Complex: A Potential Drug Target and Biomarker

Target Name: tRNA-splicing ligase complex

NCBI ID: P15810

tRNA-splicing ligase complex

Other Name(s): tRNA splicing ligase complex

tRNA-Splicing Ligase Complex: A Potential Drug Target and Biomarker

Introduction

tRNA-splicing ligase complex (tRNA splicing ligase complex) is a protein complex that plays a crucial role in the process of gene expression, which is the process by which the information encoded in DNA is translated into proteins. The tRNA splicing machinery is responsible for ensuring the accuracy and efficiency of the translation of RNA into protein. The tRNA splicing ligase complex is a protein complex that consists of multiple subunits that work together to process tRNA splicing events. This complex is located in the nucleus and has been shown to play a key role in the regulation of gene expression.

The tRNA splicing ligase complex is composed of several subunits, including the alpha subunit, the beta subunit, the gamma subunit, and the delta subunit. The alpha subunit is the primary protein component of the complex and is responsible for the recognition of tRNA splicing events . The beta subunit is responsible for the cleavage of tRNA splicing events and the gamma subunit is responsible for the binding of tRNA splicing events to the alpha subunit. The delta subunit is a smaller subunit that is responsible for the monitoring of the exon-exon splicing event.

The tRNA splicing ligase complex has been shown to play a key role in the regulation of gene expression by ensuring the accuracy and efficiency of the translation of RNA into protein. Mutations in the tRNA splicing ligase complex have been linked to a variety of genetic disorders, including splicing defects, frame-shifting mutations, and exon skipping.

Drug Targeting

The tRNA splicing ligase complex is a potential drug target due to its involvement in the regulation of gene expression. Several studies have shown that inhibitors of the tRNA splicing ligase complex have been effective in treating a variety of genetic disorders, including splicing defects, frame shifting mutation, and exon skipping.

One of the most promising compounds that has been shown to inhibit the tRNA splicing ligase complex is NEDD8, which is a non-coding RNA molecule that has been shown to function as a negative regulator of the tRNA splicing machinery. NEDD8 has been shown to interact with the alpha subunit of the tRNA splicing ligase complex and prevent it from binding to tRNA splicing events.

Another compound that has been shown to inhibit the tRNA splicing ligase complex is also a non-coding RNA molecule, called SIRT1. SIRT1 has been shown to interact with the gamma subunit of the tRNA splicing ligase complex and prevent it from binding to tRNA splicing events.

Biomarker

The tRNA splicing ligase complex is a protein complex that is expressed in a variety of tissues and cells, including muscle, heart, and brain. Therefore, it may be a potential biomarker for the diagnosis and monitoring of various diseases.

One potential use of the tRNA splicing ligase complex as a biomarker is in the diagnosis of splicing defects. Splicing defects can be caused by mutations in the tRNA splicing machinery, which can result in the production of incorrect or undigestible proteins. can be used as a biomarker to detect these types of mutations and to monitor the effectiveness of therapeutic treatments.

Another potential use of the tRNA splicing ligase complex as a biomarker is in the diagnosis of box

Protein Name: TRNA-splicing Ligase Complex

The "tRNA-splicing ligase complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about tRNA-splicing ligase complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets